DRUG · Mapped RxNorm record
degarelix
Normalized identity: degarelixView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT01990196
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
enzalutamide
Normalized identity: enzalutamideView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
trametinib
Normalized identity: trametinibView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
dasatinib
Normalized identity: dasatinibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedNeoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Interventions
degarelixDRUG · verified · RxNorm: degarelix
enzalutamideDRUG · verified · RxNorm: enzalutamide
trametinibDRUG · verified · RxNorm: trametinib
dasatinibDRUG · verified · RxNorm: dasatinib
Sponsors & collaborators
Jonsson Comprehensive Cancer Centerlead sponsor
Medivation, Inc.collaborator
GlaxoSmithKlinecollaborator
Prostate Cancer Foundationcollaborator
Astellas Pharma Inccollaborator
Novartiscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01990196 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.